155 related articles for article (PubMed ID: 28486371)
1. Trends in Mode of Hysterectomy After the U.S. Food and Drug Administration Power Morcellation Advisory.
Ottarsdottir H; Cohen SL; Cox M; Vitonis A; Einarsson JI
Obstet Gynecol; 2017 Jun; 129(6):1014-1021. PubMed ID: 28486371
[TBL] [Abstract][Full Text] [Related]
2. Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.
Multinu F; Casarin J; Hanson KT; Angioni S; Mariani A; Habermann EB; Laughlin-Tommaso SK
JAMA Surg; 2018 Jun; 153(6):e180141. PubMed ID: 29641835
[TBL] [Abstract][Full Text] [Related]
3. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.
Harris JA; Swenson CW; Uppal S; Kamdar N; Mahnert N; As-Sanie S; Morgan DM
Am J Obstet Gynecol; 2016 Jan; 214(1):98.e1-98.e13. PubMed ID: 26314519
[TBL] [Abstract][Full Text] [Related]
4. Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy.
Barron KI; Richard T; Robinson PS; Lamvu G
Obstet Gynecol; 2015 Dec; 126(6):1174-1180. PubMed ID: 26595561
[TBL] [Abstract][Full Text] [Related]
5. Minimally Invasive Hysterectomy and Power Morcellation Trends in a West Coast Integrated Health System.
Zaritsky E; Tucker LY; Neugebauer R; Chou T; Flanagan T; Walter AJ; Raine-Bennett T
Obstet Gynecol; 2017 Jun; 129(6):996-1005. PubMed ID: 28486359
[TBL] [Abstract][Full Text] [Related]
6. Complication rate of uterine morcellation in laparoscopic supracervical hysterectomy: a retrospective cohort study.
Smits RM; De Kruif JH; Van Heteren CF
Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():179-82. PubMed ID: 26943477
[TBL] [Abstract][Full Text] [Related]
7. Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation.
Stentz NC; Cooney LG; Sammel M; Shah DK
Obstet Gynecol; 2017 Jun; 129(6):1007-1013. PubMed ID: 28486366
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Morcellation Techniques at the Time of Laparoscopic Hysterectomy and Myomectomy.
Meurs EAIM; Brito LG; Ajao MO; Goggins ER; Vitonis AF; Einarsson JI; Cohen SL
J Minim Invasive Gynecol; 2017; 24(5):843-849. PubMed ID: 28483536
[TBL] [Abstract][Full Text] [Related]
9. Temporal trends in minimally invasive myomectomy before and after the US Food and Drug Administration recommendation against electric morcellation.
Pereira N; Frankel WC; Hutchinson AP; Patel HH; Mostisser C; Elias RT
Int J Gynaecol Obstet; 2017 Jun; 137(3):295-300. PubMed ID: 28218964
[TBL] [Abstract][Full Text] [Related]
10. Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications.
Mehta A; Xu T; Hutfless S; Makary MA; Sinno AK; Tanner EJ; Stone RL; Wang K; Fader AN
Am J Obstet Gynecol; 2017 May; 216(5):497.e1-497.e10. PubMed ID: 28034651
[TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?
Parker WH; Kaunitz AM; Pritts EA; Olive DL; Chalas E; Clarke-Pearson DL; Berek JS;
Obstet Gynecol; 2016 Jan; 127(1):18-22. PubMed ID: 26646134
[TBL] [Abstract][Full Text] [Related]
12. Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma.
Matsushita T; Sekizawa A; Jacobs LK
J Minim Invasive Gynecol; 2020 Jan; 27(1):178-185.e1. PubMed ID: 30936031
[TBL] [Abstract][Full Text] [Related]
13. Laparoscopic and Robotic-Assisted Hysterectomy for Uterine Leiomyomas: A Comparison of Complications and Costs.
Ngan TYT; Zakhari A; Czuzoj-Shulman N; Tulandi T; Abenhaim HA
J Obstet Gynaecol Can; 2018 Apr; 40(4):432-439. PubMed ID: 29032064
[TBL] [Abstract][Full Text] [Related]
14. Change in Surgical Practice for Women With Leiomyomas After the U.S. Food and Drug Administration Morcellator Safety Communication.
Clark NM; Schembri M; Jacoby VL
Obstet Gynecol; 2017 Nov; 130(5):1057-1063. PubMed ID: 29016511
[TBL] [Abstract][Full Text] [Related]
15. Power morcellation for women undergoing laparoscopic supracervical hysterectomy - safety of procedure and clinical experience from 426 cases.
Rechberger T; Miotła P; Futyma K; Ziętek A; Filipczak A; Rechberger E; Szumiło J; Adamiak-Godlewska A
Ginekol Pol; 2016; 87(8):546-51. PubMed ID: 27629127
[TBL] [Abstract][Full Text] [Related]
16. Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation.
Lum DA; Sokol ER; Berek JS; Schulkin J; Chen L; McElwain CA; Wright JD
J Minim Invasive Gynecol; 2016; 23(4):548-56. PubMed ID: 26827905
[TBL] [Abstract][Full Text] [Related]
17. The impact of surgeon volume on perioperative adverse events in women undergoing minimally invasive hysterectomy for the large uterus.
Bretschneider CE; Frazzini Padilla P; Das D; Jelovsek JE; Unger CA
Am J Obstet Gynecol; 2018 Nov; 219(5):490.e1-490.e8. PubMed ID: 30222939
[TBL] [Abstract][Full Text] [Related]
18. Current Issues with Hysterectomy.
Barker MA
Obstet Gynecol Clin North Am; 2016 Sep; 43(3):591-601. PubMed ID: 27521886
[TBL] [Abstract][Full Text] [Related]
19. Hysterectomy Practice Patterns in the Postmorcellation Era.
Jorgensen EM; Modest AM; Hur HC; Hacker MR; Awtrey CS
Obstet Gynecol; 2019 Apr; 133(4):643-649. PubMed ID: 30870280
[TBL] [Abstract][Full Text] [Related]
20. Laparoscopic myomectomy and morcellation: A review of techniques, outcomes, and practice guidelines.
Glaser LM; Friedman J; Tsai S; Chaudhari A; Milad M
Best Pract Res Clin Obstet Gynaecol; 2018 Jan; 46():99-112. PubMed ID: 29078975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
